Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Helsinn Healthcare S.A., Eisai announce signing of licensing agreement

Helsinn Healthcare S.A. and Eisai Inc. today announce the signing of a licensing agreement granting Eisai Inc. commercialization rights for a new product for potential use in the prevention of chemotherapy-induced nausea and vomiting in the United States.

9 Jun 2010

S*BIO completes enrollment in SB1518 JAK2 inhibitor Phase 2 clinical trials for myelofibrosis

S*BIO Pte Ltd today announced that it has completed enrollment of patients in two separate Phase 2 clinical trials for its potent and orally-active JAK2 inhibitor SB1518 at multiple clinical sites in the U.S. and Australia for the treatment of myelofibrosis (MF).

9 Jun 2010

Accuray forms strategic alliance with Siemens

Accuray, a global leader in the field of radiosurgery, today announced that it has formed a strategic alliance with Siemens. The strategic alliance is expected to extend the global sales reach for Accuray's CyberKnife Robotic Radiosurgery System while creating a research-and-development alliance aimed at developing and commercializing innovative new technologies and products.

9 Jun 2010

Cardinal Health to purchase Healthcare Solutions Holding for $517M

Cardinal Health today announced plans to expand its presence in specialty pharmaceutical services with a definitive agreement to purchase Healthcare Solutions Holding, LLC in an upfront $517 million all-cash transaction. The agreement also includes the opportunity for earn-out payments of up to $150 million over the next three years.

9 Jun 2010

Human Genome Sciences reports results of mapatumumab Phase 2 trial for multiple myeloma

Human Genome Sciences, Inc. today announced the results of its randomized Phase 2 trial of mapatumumab (HGS-ETR1) in combination with bortezomib (Velcade) in patients with advanced multiple myeloma.

9 Jun 2010

Four-year follow-up results from SPRYCEL Phase 3 study in CML-CP presented at ASCO

Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced four-year follow-up results from a Phase 3 randomized, open-label, dose-optimization study of SPRYCEL® (dasatinib) in chronic-phase chronic myeloid leukemia (CML-CP) patients resistant or intolerant to Gleevec®* (imatinib mesylate). At four years, for all patients administered SPRYCEL 100 mg once daily, overall survival was 82% (95% CI: 76%-88%) and progression-free survival was 66% (95% CI: 57%-74%).

9 Jun 2010

Stress-reducing psychological intervention helps increase quality of life among women with breast cancer

Stress-reducing psychological intervention helps to increase survival and quality of life among women with recurrent breast cancer over the long-term, according to results of a Phase III study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

9 Jun 2010

Tumors not likely to worsen during active surveillance period in low risk prostate cancer patients

Johns Hopkins experts have found that men enrolled in an active surveillance program for prostate cancer that eventually needed surgery to remove their prostates fared just as well as men who opted to remove the gland immediately, except if a follow-up biopsy during surveillance showed high-grade cancer.

9 Jun 2010

Experts call on international community to commit attention and resources to cervical cancer prevention

Women's health leaders today called on the international community to commit the resources needed to ensure that women and girls worldwide have equal access to cervical cancer prevention technologies. At the WOMEN DELIVER conference, the Declaration for Universal Access to Cervical Cancer Prevention was issued by leading women's health, cancer and business organizations, including PATH, the International Planned Parenthood Federation and the International Union Against Cancer.

9 Jun 2010

Multiple presentations on nab-driven chemotherapy at 46th ASCO

Abraxis BioScience, Inc. presented abstracts describing 10 trials of nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension), for the treatment of breast cancer at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

9 Jun 2010

White paper advocates strategies to reduce barriers to HPV vaccination, cervical cancer prevention

The Society of Gynecologic Oncologists has published its third in a series of four papers on a variety of cervical cancer issues and topics featured at "The Future Strategies for Cervical Cancer Prevention: What Do We Need to Do Now to Prepare" Forum. The paper, entitled "Can the Barriers to HPV Vaccination in High-Risk Populations be Overcome?" appears in the June, 2010 issue of Gynecologic Oncology Journal.

9 Jun 2010

Phase 3 clinical study: Ipilimumab boosts, sustains immune system responses against melanoma tumors

The Cancer Research Institute, a nonprofit organization dedicated to the development of immune system-based treatments for cancer, announced today its celebration of a significant new breakthrough in the treatment of melanoma, the deadliest form of skin cancer. The new treatment, a cancer immunotherapy created by Cancer Research Institute Scientific Advisory Council Associate Director James P. Allison, Ph.D., is designed to "take the brakes off the immune system," and is the first treatment ever proven to extend life for patients whose melanomas are unresponsive to existing cancer therapies.

9 Jun 2010

Clinical trials of four investigational compounds in solid tumors presented at ASCO Annual Meeting

Millennium: The Takeda Oncology Company today announced data from clinical trials of four investigational compounds in solid tumors presented at the Annual Meeting of the American Society of Clinical Oncology, held in Chicago, Illinois, June 4-8, 2010. These data include an oral presentation on MLN8237, the Company's selective Aurora A kinase inhibitor.

9 Jun 2010

Myriad Pharmaceuticals announces strategic initiatives to focus on oncology pipeline

Myriad Pharmaceuticals, Inc. today announced several strategic initiatives to focus the Company's efforts on its oncology pipeline and to conserve its financial resources to extend the Company's projected cash runway beyond 2013.

9 Jun 2010

Astellas Pharma acquires OSI Pharmaceuticals for $4.0 billion

Astellas Pharma Inc. announced today that the company has completed its acquisition of OSI Pharmaceuticals, Inc. for $4.0 billion.

9 Jun 2010

$Pivotal trial data of zalutumumab in refractory head and neck cancer patients presented at ASCO 2010$

Pivotal trial data of zalutumumab in refractory head and neck cancer patients presented at ASCO 2010

Genmab A/S announced today that data from the pivotal trial of zalutumumab in refractory head and neck cancer patients will be presented today at the 2010 American Society of Clinical Oncology Annual Meeting, which will be held June 1-8 in Chicago, Illinois. This is the first controlled study to demonstrate that an EGFr-targeted antibody given as monotherapy induces a clinically meaningful improvement in progression free survival in patients with refractory head and neck cancer who have failed platinum-based chemotherapy.

9 Jun 2010

Blood vessel-blocking drug slows prostate cancer progression: Experts

A blood vessel-blocking drug called tasquinimod slowed the rate of disease progression in a clinical trial of 200 prostate cancer patients, according to experts at Johns Hopkins, Roswell Park Cancer Institute and Duke University.

9 Jun 2010

Clinical results from the use of hyperthermia to treat cervical cancer presented at ESHO meeting

BSD Medical Corporation today reported significant clinical results from the use of hyperthermia to treat cervical cancer. The results were presented at the annual meeting of the European Society for Hyperthermic Oncology, which was held in Rotterdam, The Netherlands, on May 19 to 21, 2010.

9 Jun 2010

GE Healthcare to present anti-[18F]FACBC phase 1 study results at Society of Nuclear Medicine annual meeting

GE Healthcare, a unit of the General Electric Company, today will present results of a phase 1 study of anti-[18F]FACBC at the 57th annual meeting of the Society of Nuclear Medicine in Salt Lake City, Utah. The presentation closely follows the launch of the phase 2 clinical development program for anti-[18F]FACBC, which was initially discovered and developed by Emory University, Atlanta, Georgia, and was licensed to Nihon Medi-Physics Co., Ltd. (NMP) of Japan.

9 Jun 2010

Lytix Biopharma, KAEL-GemVax granted approval for GV1001/LTX-315 combination cancer therapy study

The Norwegian biopharmaceutical company Lytix Biopharma and Korean company KAEL-GemVax today announced approval by the Norwegian Medicines Agency ('Statens Legemiddelverk') to test a combination of LTX-315 and GV1001 as vaccine therapy in patients with resected tumours. Lytix Biopharma CEO Gunnar Salid states, "We are delighted to announce the approval of our joint study to test a combination of two very interesting experimental drugs.

9 Jun 2010

Oncology News and Research

Further Reading

Helsinn Healthcare S.A., Eisai announce signing of licensing agreement

S*BIO completes enrollment in SB1518 JAK2 inhibitor Phase 2 clinical trials for myelofibrosis

Accuray forms strategic alliance with Siemens

Cardinal Health to purchase Healthcare Solutions Holding for $517M

Human Genome Sciences reports results of mapatumumab Phase 2 trial for multiple myeloma

Four-year follow-up results from SPRYCEL Phase 3 study in CML-CP presented at ASCO

Stress-reducing psychological intervention helps increase quality of life among women with breast cancer

Tumors not likely to worsen during active surveillance period in low risk prostate cancer patients

Experts call on international community to commit attention and resources to cervical cancer prevention

Multiple presentations on nab-driven chemotherapy at 46th ASCO

White paper advocates strategies to reduce barriers to HPV vaccination, cervical cancer prevention

Phase 3 clinical study: Ipilimumab boosts, sustains immune system responses against melanoma tumors

Clinical trials of four investigational compounds in solid tumors presented at ASCO Annual Meeting

Myriad Pharmaceuticals announces strategic initiatives to focus on oncology pipeline

Astellas Pharma acquires OSI Pharmaceuticals for $4.0 billion

Pivotal trial data of zalutumumab in refractory head and neck cancer patients presented at ASCO 2010

Blood vessel-blocking drug slows prostate cancer progression: Experts

Clinical results from the use of hyperthermia to treat cervical cancer presented at ESHO meeting

GE Healthcare to present anti-[18F]FACBC phase 1 study results at Society of Nuclear Medicine annual meeting

Lytix Biopharma, KAEL-GemVax granted approval for GV1001/LTX-315 combination cancer therapy study

Cancer Research eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News